ABSTRACT
Olfactory ectomesenchymal stem cells (OE-MSCs) possess the immunosuppressive activity and regeneration capacity and hold a lot of promises for neurodegenerative disorders treatment. This study aimed to determine OE-MSCs which are able to augment and differentiate into functional neurons and regenerate the CNS and also examine whether the implantation of OE-MSCs in the pars compacta of the substantia nigra (SNpc) can improve Parkinson's symptoms in a rat model-induced with 6-hydroxydopamine. We isolated OE-MSCs from lamina propria in olfactory mucosa and characterized them using flow cytometry and immunocytochemistry. The therapeutic potential of OE-MSCs was evaluated by the transplantation of isolated cells using a rat model of acute SN injury as a Parkinson's disease. Significant behavioral improvement in Parkinsonian rats was elicited by the OE-MSCs. The results demonstrate that the expression of PAX2, PAX5, PITX3, dopamine transporter, and tyrosine hydroxylase was increased by OE-MSCs compared to the control group which is analyzed with real-time polymerase chain reaction technique and immunohistochemical staining. In the outcome, the transplantation of 1,1'-dioctadecyl-3,3,3'3'-tetramethyl indocarbocyanine perchlorate labeled OE-MSCs that were fully differentiated to dopaminergic neurons contribute to a substantial improvement in patients with Parkinson's. Together, our results provide that using OE-MSCs in neurodegenerative disorders might lead to better neural regeneration.
Subject(s)
Dopaminergic Neurons/cytology , Mesenchymal Stem Cell Transplantation , Mesenchymal Stem Cells/cytology , Olfactory Mucosa/cytology , Parkinson Disease/therapy , Animals , Cell- and Tissue-Based Therapy/methods , Cells, Cultured , Dopamine Plasma Membrane Transport Proteins/biosynthesis , Homeodomain Proteins/biosynthesis , Male , Mesenchymal Stem Cells/metabolism , PAX2 Transcription Factor/biosynthesis , PAX5 Transcription Factor/biosynthesis , Rats , Rats, Wistar , Transcription Factors/biosynthesis , Tyrosine 3-Monooxygenase/biosynthesisABSTRACT
Novel immune checkpoint blockades, including those targeting CD73 and A2aR, are being evaluated in malignancies in clinical trials. Here, we investigated the expression of CD73 and A2aR as well as tumor-infiltrating lymphocytes (TILs), and analyzed their correlations with clinicopathological characteristics and survival in diffuse large B-cell lymphoma (DLBCL). We found that CD73 expression on tumor cells, rather than the total protein and gene levels of CD73, was associated with survival. Patients with CD73+ /Pax-5+ (median survival, 57.8 months; 95% CI, 46.4-69.3) experienced significantly poorer outcomes than those with CD73- /Pax-5+ (median survival, 73.5 months; 95% CI, 65.9-81.2). Additionally, A2aR expression on both total TILs and CD8+ TILs was correlated with survival. Patients with A2aR+ TILs (median survival, 53.3 months; 95% CI, 40.6-66.0) had a significantly shorter survival time than patients with A2aR- TILs (median survival, 74.5 months; 95% CI, 67.5-81.5). Spearman's rank test showed that CD73 expression on tumor cells was positively correlated with A2aR expression on TILs (R = 0.395, p = 0.001). We further found that patients could be more precisely stratified through the combination of CD73 tumor cell expression and A2aR TILs expression, and patients with CD73+ /Pax-5+ and A2aR+ TILs experienced the worst outcome. We also revealed that patients with CD73+ /Pax-5+ and low CD8+ TILs or low absolute lymphocyte counts had unfavorable outcomes. Overall, our findings uncovered that patients with CD73+ on tumor cells as well as A2aR+ on TILs or low CD8+ TILs exhibited inferior survival, supporting potential combination strategies using CD73/A2aR immunosuppressive blockades as treatment options for DLBCL patients.
Subject(s)
5'-Nucleotidase/immunology , Lymphocytes, Tumor-Infiltrating/immunology , Lymphoma, Large B-Cell, Diffuse/immunology , Receptor, Adenosine A2A/immunology , 5'-Nucleotidase/biosynthesis , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Biomarkers, Tumor/biosynthesis , Biomarkers, Tumor/immunology , CD8-Positive T-Lymphocytes/immunology , Cyclophosphamide/administration & dosage , Doxorubicin/administration & dosage , Female , GPI-Linked Proteins/biosynthesis , GPI-Linked Proteins/immunology , Humans , Lymphoma, Large B-Cell, Diffuse/drug therapy , Lymphoma, Large B-Cell, Diffuse/pathology , Male , Middle Aged , PAX5 Transcription Factor/biosynthesis , PAX5 Transcription Factor/immunology , Prednisone/administration & dosage , Receptor, Adenosine A2A/biosynthesis , Rituximab/administration & dosage , Signal Transduction/immunology , Survival Rate , Vincristine/administration & dosageABSTRACT
BACKGROUND: Merkel cell carcinoma (MCC) tumor samples frequently express B-lymphoid lineage markers. However, the reasons for expression of specific B-lymphoid lineage markers are still unclear. We studied the expression of TdT and PAX5 (two B-cell lymphoid lineage markers) in a large pool of MCC tissue microarray samples. METHODS: Immunoexpression and staining intensities of TdT and Pax-5 were statistically correlated with patient, tumor, Merkel cell polyomavirus (MCV), and disease-specific parameters. RESULTS: In a cohort of 117 MCC patients and their corresponding tumor samples, TdT was expressed in 37 (31.6%) samples and PAX5 in 26 (22.2%). Simultaneous immunostaining for TdT and PAX5 was observed in 13 (11.1%) samples. A statistically significant relationship was observed between MCV virus copy number and positive TdT expression (P = 0.0056). Similarly, a significant relationship was also observed between positive TdT and tumor MCV virus positivity (P = 0.000495). CONCLUSION: We observed frequent TdT and PAX5 immunoexpression in MCC tumor samples. However, simultaneous immunoexpression of these markers was scarce. TdT expression was statistically significantly associated with MCV positivity. The absence of a statistically significant association between tumor parameters and disease progression markers undermines the systemic use of these markers in clinical practice.
Subject(s)
Carcinoma, Merkel Cell/metabolism , DNA Nucleotidylexotransferase/biosynthesis , DNA, Viral/metabolism , Gene Expression Regulation, Neoplastic , Merkel cell polyomavirus/metabolism , Neoplasm Proteins/biosynthesis , PAX5 Transcription Factor/biosynthesis , Polyomavirus Infections/metabolism , Skin Neoplasms/metabolism , Tumor Virus Infections/metabolism , Aged , Aged, 80 and over , Carcinoma, Merkel Cell/pathology , Carcinoma, Merkel Cell/virology , Female , Humans , Male , Middle Aged , Polyomavirus Infections/pathology , Skin Neoplasms/pathology , Skin Neoplasms/virology , Tumor Virus Infections/pathologyABSTRACT
Paired Box 5 (PAX5), a well-established B-cell marker, is preferentially expressed in small cell lung carcinoma and regulates the transcription of c-Met, offering a potential for therapeutic target. Its expression in poorly differentiated neuroendocrine carcinoma (PDNEC) of the digestive system has not been systemically evaluated. Archived pathology materials from 38 PDNEC in the gastrointestinal (GI) and pancreatobiliary (PB) tract were reviewed. Representative tumor sections were subject to immunohistochemical stain for PAX5, c-Met, and CD20. The extent of the staining [focal (<10%), patchy (10% to 50%), and diffuse (>50%)] and intensity (1+ to 3+) was evaluated. In total, 38 cases of well-differentiated neuroendocrine tumors from GI/PB tract served as controls. Nuclear PAX5 staining was observed in 16 (42%) cases in total, in 46% (11/24) of large cell neuroendocrine carcinoma, 67% (4/6) of small cell neuroendocrine carcinoma, and 13% (1/8) of mixed adenoneuroendocrine carcinoma, with diffuse (8), patchy (4), or focal (4) staining. The intensity was 3+ (2), 2+ (6), and 1+ (8). PAX5 expression was common in ampullary (4/5) and gastroesophageal junctional/esophageal (5/9) PDNEC. Two (5%) of 38 well-differentiated neuroendocrine tumors were positive for PAX5. Three PAX5 positive PDNEC showed weak cytoplasmic c-Met immunolabeling. CD20 was negative in all tumors. Our data show that PAX5 is commonly expressed in PDNEC of the GI/PB tract including small cell neuroendocrine carcinoma. This observation warrants a cautious approach when interpreting small biopsy of poorly differentiated neoplasms, especially when lymphoma is considered in the differentials. Further study of PAX5/c-Met signaling pathway and its potential therapeutic value in GI/PB PDNEC is warranted.
Subject(s)
Adenocarcinoma , Carcinoma, Large Cell , Carcinoma, Neuroendocrine , Carcinoma, Small Cell , Digestive System Neoplasms , Gene Expression Regulation, Neoplastic , Neoplasm Proteins/biosynthesis , PAX5 Transcription Factor/biosynthesis , Adenocarcinoma/diagnosis , Adenocarcinoma/metabolism , Adenocarcinoma/pathology , Adenocarcinoma/therapy , Aged , Aged, 80 and over , Biopsy , Carcinoma, Large Cell/diagnosis , Carcinoma, Large Cell/metabolism , Carcinoma, Large Cell/pathology , Carcinoma, Large Cell/therapy , Carcinoma, Neuroendocrine/diagnosis , Carcinoma, Neuroendocrine/metabolism , Carcinoma, Neuroendocrine/pathology , Carcinoma, Neuroendocrine/therapy , Carcinoma, Small Cell/metabolism , Carcinoma, Small Cell/pathology , Carcinoma, Small Cell/therapy , Digestive System Neoplasms/diagnosis , Digestive System Neoplasms/metabolism , Digestive System Neoplasms/pathology , Digestive System Neoplasms/therapy , Female , Humans , Male , Middle AgedABSTRACT
BACKGROUND: A high-level expression of the CRLF2 gene is frequent in precursor B-cell acute lymphoblastic leukemia (pB-ALL) and can be caused by different genetic aberrations. The presence of the most frequent alteration, the P2RY8/CRLF2 fusion, was shown to be associated with a high relapse incidence in children treated according to ALL-Berlin-Frankfurt-Münster (BFM) protocols, which is poorly understood. Moreover, the frequency of other alterations has not been systematically analyzed yet. PROCEDURE: CRLF2 mRNA expression and potential genetic aberrations causing a CRLF2 high expression were prospectively assessed in 1,105 patients treated according to the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP)-BFM ALL 2009 protocol. Additionally, we determined copy number alterations in selected B-cell differentiation genes for all CRLF2 high-expressing pB-ALL cases, as well as JAK2 and CRLF2 mutations. RESULTS: A CRLF2 high expression was detected in 26/178 (15%) T-cell acute lymphoblastic leukemia (T-ALL) cases, 21 of them (81%) had been stratified as high-risk patients by treatment response. In pB-ALL, a CRLF2 high expression was determined in 91/927 (10%) cases; the P2RY8/CRLF2 rearrangement in 44/91 (48%) of them, supernumerary copies of CRLF2 in 18/91 (20%), and, notably, the IGH/CRLF2 translocation was detected in 16/91 (18%). Remarkably, 7 of 16 (44%) patients with IGH/CRLF2 translocation had already relapsed. P2RY8/CRLF2- and IGH/CRLF2-positive samples (70 and 94%, respectively) were characterized by a high frequency of additional deletions in B-cell differentiation genes such as IKZF1 or PAX5. CONCLUSION: Our data suggest that this high frequency of genetic aberrations in the context of a high CRLF2 expression could contribute to the high risk of relapse in P2RY8/CRLF2- and IGH/CRLF2-positive ALL.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Gene Expression Regulation, Leukemic/drug effects , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Precursor Cell Lymphoblastic Leukemia-Lymphoma/metabolism , Receptors, Cytokine/biosynthesis , Adolescent , Asparaginase/administration & dosage , Child , Child, Preschool , Daunorubicin/administration & dosage , Female , Gene Rearrangement , Humans , Ikaros Transcription Factor/biosynthesis , Ikaros Transcription Factor/genetics , Infant , Male , Oncogene Proteins, Fusion/biosynthesis , Oncogene Proteins, Fusion/genetics , PAX5 Transcription Factor/biosynthesis , PAX5 Transcription Factor/genetics , Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics , Prednisone/administration & dosage , Receptors, Cytokine/genetics , Receptors, Purinergic P2Y/biosynthesis , Receptors, Purinergic P2Y/genetics , Vincristine/administration & dosageABSTRACT
Anaplastic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma (ALCL) is a subtype of T-cell lymphomas that may mimic several other malignancies morphologically. With the help of immunohistochemistry, most cases of ALCL can be diagnosed on the basis of expression of T-cell lineage associated antigens. However, aberrations in the expression of immunohistochemical markers pose diagnostic challenges. The morphological and immunophenotypic features of ALCL show considerable overlap with classical Hodgkin lymphoma (CHL), which is a B-cell lymphoma. The 2008 World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues suggests that staining for the B-cell transcription factor, paired box 5 (PAX-5), is helpful in differentiating between them, as it is weakly positive in most CHL and should be negative in ALCL. We report a rare case of ALK-negative ALCL, which was positive for PAX-5 and CD15, mimicking CHL by immunohistochemistry, resulting in a diagnostic dilemma.
Subject(s)
Biomarkers, Tumor/analysis , Lymphoma, Large-Cell, Anaplastic/diagnosis , Lymphoma, Large-Cell, Anaplastic/pathology , PAX5 Transcription Factor/biosynthesis , Aged , Anaplastic Lymphoma Kinase , Diagnosis, Differential , Female , Hodgkin Disease/diagnosis , Hodgkin Disease/pathology , Humans , PAX5 Transcription Factor/analysis , Receptor Protein-Tyrosine KinasesABSTRACT
BACKGROUND & OBJECTIVES: The PAX5, a paired box transcription factor and B-cell activator protein (BSAP), activates B-cell commitment genes and represses non-B-cell lineage genes. About 14 transcript variants of PAX5 have been observed in human. Any alteration in its expression pattern leads to lymphogenesis or associated diseases and carcinogenesis in non-lymphoid tissues. Its mechanisms of function in pathophysiology of non-Hodgkin's lymphoma (NHL) are unclear. This study was intended to explore influence of PAX5 in cascade of NHL pathogenesis and diagnosis. METHODS: Samples of 65 patients were evaluated by immunohistochemical staining for cellular localization of PAX5, CD19, CD3, cABL, p53, Ras and Raf and by TUNEL assay, RNA-isolation and reverse transcriptase (RT)-PCR, w0 estern blot analysis, and lactate dehydrogenase (LDH) specific staining. RESULTS: B-cell type NHL patients were positive for PAX5, p53, Ras, CD19, Raf and CD3. All of them showed TUNEL-positive cells. The differential expression pattern of PAX5, CD19, p53, CD3, Zap700 , HIF 1α, Ras, Raf and MAPK (mitogen-activated protein kinase) at the levels of transcripts and proteins was observed. The LDH assay showed modulation of LDH4 and LDH5 isoforms in the lymph nodes of NHL patients. INTERPRETATION & CONCLUSIONS: The histological observations suggested that the patients represent diverse cases of NHL like mature B-cell type, mature T-cell type and high grade diffuse B-cell type NHL. The findings indicate that patients with NHL may also be analyzed for status of PAX5, CD19 and ZAP70, and their transcriptional and post-translational variants for the differential diagnosis of NHL and therapy.
Subject(s)
Antigens, CD19/genetics , Lymphoma, B-Cell/diagnosis , Lymphoma, Non-Hodgkin/diagnosis , Lymphoma, T-Cell/diagnosis , PAX5 Transcription Factor/genetics , ZAP-70 Protein-Tyrosine Kinase/genetics , Aged , Antigens, CD19/biosynthesis , Diagnosis, Differential , Female , Humans , Lymphoma, B-Cell/genetics , Lymphoma, Non-Hodgkin/classification , Lymphoma, Non-Hodgkin/genetics , Lymphoma, T-Cell/genetics , Male , Middle Aged , PAX5 Transcription Factor/biosynthesis , Pathology, Molecular , Protein Processing, Post-Translational/genetics , Transcription, Genetic , ZAP-70 Protein-Tyrosine Kinase/biosynthesisABSTRACT
The aim of our study was to evaluate the immunohistochemical expression of SOX11, PAX5, TTF-1 and ISL-1 in medulloblastoma (MB) to investigate their diagnostic usefulness. METHODS: Immunohistochemical expression of PAX5 (two antibodies: Dako, DAK-Pax5; and BD, clone 24), TTF-1 (Dako, 8G7G3/1), SOX11 (CL0142; Abcam) and ISL-1 (1 H9, Abcam) was analyzed using the h-score and Remmele score in 25 cases of MB. RESULTS: There were 18 MBs of classic and 7 of desmoplastic type. SOX11 was strongly expressed in all tumors. The expression of PAX5 was higher and more frequent in a case of DAK-Pax5 clone (25/25) than clone 24 (6/25). ISL-1 was positive in 11 (44%) and TTF-1 in 3 (12%) cases. ISL-1 expression correlated positively (p<0.001), while TTF-1 correlated negatively with the age of patients (p=0.039). PAX5 expression correlated with ISL-1 (p=0.039) and showed a trend toward higher expression in the desmoplastic subtype (p=0.069). CONCLUSIONS: SOX11 is strongly and robustly expressed in MBs. PAX5 expression pattern differs substantially among two antibody clones. TTF-1 and ISL-1 is associated with the age of patients.
Subject(s)
Cerebellar Neoplasms/diagnosis , DNA-Binding Proteins/biosynthesis , LIM-Homeodomain Proteins/biosynthesis , Medulloblastoma/diagnosis , PAX5 Transcription Factor/biosynthesis , SOXC Transcription Factors/biosynthesis , Transcription Factors/biosynthesis , Adolescent , Adult , Biomarkers, Tumor/analysis , Cerebellar Neoplasms/metabolism , Child , Child, Preschool , DNA-Binding Proteins/analysis , Female , Humans , Immunohistochemistry , Infant , LIM-Homeodomain Proteins/analysis , Male , Medulloblastoma/metabolism , PAX5 Transcription Factor/analysis , SOXC Transcription Factors/analysis , Transcription Factors/analysis , Young AdultABSTRACT
Olfactory neuroblastoma (ONB) is a rare neoplasm of the sinonasal area with neuroendocrine differentiation. ISL-1, TTF-1 and PAX5 are transcription factors that are frequently upregulated in tumors showing neuroendocrine differentiation. The aim of our study was to evaluate these markers in a group of ONBs. We included 11 ONBs from 4 large university hospitals. Immunohistochemical expression of TTF-1, PAX5 and ISL-1 was evaluated. TTF-1, ISL-1 and PAX5 were expressed in 3/11 cases (27.27%, h-score: 3-45), 7/11 cases (63.64%, h-score: 23-200), and in 3/11 cases (27.77%, h-score 3-85), respectively. The patient with the strongest PAX5 reactivity exhibited an aggressive clinical course with rapid dissemination to the spine and death shortly after the diagnosis. No significant correlation in the expression of PAX5 and TTF-1 (ï² = 0.43; p = 0.18) was observed. ISL-1 is widely expressed in tumors with neuroendocrine differentiation and therefore of limited value in their differential diagnosis. TTF-1 positivity does not exclude the diagnosis of primary ONB, although usually only a small percentage of cells are positive. PAX5 expression is infrequent (27.27%) in ONB; however, if present it can be associated with a very aggressive clinical course.
Subject(s)
DNA-Binding Proteins/biosynthesis , Esthesioneuroblastoma, Olfactory/metabolism , LIM-Homeodomain Proteins/biosynthesis , Nose Neoplasms/metabolism , PAX5 Transcription Factor/biosynthesis , Transcription Factors/biosynthesis , Adult , Aged , Aged, 80 and over , Biomarkers, Tumor/analysis , DNA-Binding Proteins/analysis , Esthesioneuroblastoma, Olfactory/pathology , Female , Humans , Immunohistochemistry , LIM-Homeodomain Proteins/analysis , Male , Middle Aged , Nasal Cavity/pathology , Nose Neoplasms/pathology , PAX5 Transcription Factor/analysis , Transcription Factors/analysis , Young AdultABSTRACT
The mouse zinc-finger gene Zfp521 (also known as ecotropic viral insertion site 3; Evi3; and ZNF521 in humans) has been identified as a B-cell proto-oncogene, causing leukemia in mice following retroviral insertions in its promoter region that drive Zfp521 over-expression. Furthermore, ZNF521 is expressed in human hematopoietic cells, and translocations between ZNF521 and PAX5 are associated with pediatric acute lymphoblastic leukemia. However, the regulatory factors that control Zfp521 expression directly have not been characterized. Here we demonstrate that the transcription factors SPI1 (PU.1) and HOXC13 synergistically regulate Zfp521 expression, and identify the regions of the Zfp521 promoter required for this transcriptional activity. We also show that SPI1 and HOXC13 activate Zfp521 in a dose-dependent manner. Our data support a role for this regulatory mechanism in vivo, as transgenic mice over-expressing Hoxc13 in the fetal liver show a strong correlation between Hoxc13 expression levels and Zfp521 expression. Overall these experiments provide insights into the regulation of Zfp521 expression in a nononcogenic context. The identification of transcription factors capable of activating Zfp521 provides a foundation for further investigation of the regulatory mechanisms involved in ZFP521-driven cell differentiation processes and diseases linked to Zfp521 mis-expression.
Subject(s)
Homeodomain Proteins/genetics , Leukemia/genetics , Proto-Oncogene Proteins/genetics , Trans-Activators/genetics , Transcription Factors/genetics , Transcriptional Activation/genetics , Animals , B-Lymphocytes/metabolism , Cell Differentiation/genetics , Gene Expression Regulation, Leukemic , Homeodomain Proteins/biosynthesis , Humans , Leukemia/pathology , Mice , Mice, Transgenic , PAX5 Transcription Factor/biosynthesis , PAX5 Transcription Factor/genetics , Promoter Regions, Genetic , Proto-Oncogene Mas , Proto-Oncogene Proteins/biosynthesis , Retroviridae/genetics , Trans-Activators/biosynthesis , Transcription Factors/biosynthesisABSTRACT
Chronic lymphocytic leukaemia (CLL) is a frequent disease in which the genetic alterations determining the clinicobiological behaviour are not fully understood. Here we describe a comprehensive evaluation of the genomic landscape of 452 CLL cases and 54 patients with monoclonal B-lymphocytosis, a precursor disorder. We extend the number of CLL driver alterations, including changes in ZNF292, ZMYM3, ARID1A and PTPN11. We also identify novel recurrent mutations in non-coding regions, including the 3' region of NOTCH1, which cause aberrant splicing events, increase NOTCH1 activity and result in a more aggressive disease. In addition, mutations in an enhancer located on chromosome 9p13 result in reduced expression of the B-cell-specific transcription factor PAX5. The accumulative number of driver alterations (0 to ≥4) discriminated between patients with differences in clinical behaviour. This study provides an integrated portrait of the CLL genomic landscape, identifies new recurrent driver mutations of the disease, and suggests clinical interventions that may improve the management of this neoplasia.
Subject(s)
Leukemia, Lymphocytic, Chronic, B-Cell/genetics , Mutation/genetics , 3' Untranslated Regions/genetics , Alternative Splicing/genetics , B-Lymphocytes/metabolism , Carrier Proteins/genetics , Chromosomes, Human, Pair 9/genetics , DNA Mutational Analysis , DNA, Neoplasm/genetics , DNA-Binding Proteins , Enhancer Elements, Genetic/genetics , Genomics , Humans , Leukemia, Lymphocytic, Chronic, B-Cell/metabolism , Leukemia, Lymphocytic, Chronic, B-Cell/pathology , Nerve Tissue Proteins/genetics , Nuclear Proteins/genetics , PAX5 Transcription Factor/biosynthesis , PAX5 Transcription Factor/genetics , Protein Tyrosine Phosphatase, Non-Receptor Type 11/genetics , Receptor, Notch1/genetics , Receptor, Notch1/metabolism , Transcription Factors/geneticsABSTRACT
Germinal center (GC) reaction is a T cell-dependent process in which activated B cells undergo clonal expansion and functional maturation to produce high affinity antibodies and differentiate into memory B cells(1). Here we demonstrate a new role of bromodomain and extraterminal domain (BET) protein BRD4 in GC B cell development. We found that during B cell differentiation stage there was an elevated expression of BRD4 in GC B cells and inhibition of BRD4 by small molecule inhibitors led to the suppression of GC formation and correspondent antibody responses in a Td antigen immunization model. At the molecular level, we found that the effects of BRD4 in primary GC B cell differentiation and B cell lymphoma were mediated through the impaired phosphorylation and translocation of NF-κBp65 and further down-regulation of B-cell lymphoma 6 (Bcl6) expression. Thus this study reveals a novel function of BRD4 in controlling the GC B cell development pathway.
Subject(s)
B-Lymphocytes/cytology , Germinal Center/immunology , Nuclear Proteins/physiology , Proto-Oncogene Proteins c-bcl-6/immunology , Transcription Factor RelA/immunology , Transcription Factors/physiology , Animals , Antibodies/blood , Antibodies/immunology , Azepines/pharmacology , B-Lymphocytes/immunology , Basic-Leucine Zipper Transcription Factors/biosynthesis , CD4-Positive T-Lymphocytes/immunology , Cell Cycle Proteins , Cell Differentiation/immunology , Gene Expression Regulation/immunology , Humans , Interferon Regulatory Factors/biosynthesis , Lymphocyte Activation/immunology , Lymphoma, B-Cell/pathology , Mice , Mice, Inbred C57BL , Nuclear Proteins/genetics , Nucleoproteins/immunology , PAX5 Transcription Factor/biosynthesis , Phosphorylation , Proto-Oncogene Proteins c-bcl-6/biosynthesis , Proto-Oncogene Proteins c-bcl-6/genetics , RNA Interference , RNA, Messenger/biosynthesis , RNA, Small Interfering , Signal Transduction/immunology , Transcription Factor RelA/metabolism , Transcription Factors/genetics , Triazoles/pharmacologyABSTRACT
Pax5 transcription factor, also known as B-cell specific activator protein (BSAP), plays a dual role in the hematopoietic system. Pax5 expression is essential in B-cell precursors for normal differentiation and maturation of B-cells. On the other hand, it inhibits the differentiation and progress toward other lineages. The expression of this factor is involved in several aspects of B-cell differentiation, including commitment, immunoglobulin gene rearrangement, BCR signal transduction and B-cell survival, so that the deletion or inactivating mutations of Pax5 cause cell arrest in Pro-B-cell stage. In recent years, point mutations, deletions and various rearrangements in Pax5 gene have been reported in several types of human cancers. However, no clear relationship has been found between these aberrations and disease prognosis. Specific expression of Pax5 in B-cells can raise it as a marker for the diagnosis and differentiation of B-cell leukemias and lymphomas as well as account for remission or relapse. Extensive studies on Pax5 along with other genes and immunomarkers are necessary for decisive results in this regard.
Subject(s)
Biomarkers, Tumor/analysis , Leukemia/diagnosis , PAX5 Transcription Factor/biosynthesis , Humans , Leukemia/mortality , PrognosisABSTRACT
Lung cancer is the leading cause of cancer-related death in both men and women and consists of different histological types. Histopathological examination and accurate subtype diagnosis has become increasingly important in guiding patient management and, as such, is the most important currently available lung cancer "biomarker". In this study, we examined the expression of PAX2 and PAX5 by immunohistochemistry in 47 cases of lung cancer and 13 cases of pneumonia. The results demonstrated that PAX2 were detected in 82.8% (24/29) of NSCLC, 0% (0/18) of SCLC and 7.7% (1/13) of pneumonia, respectively; However, PAX5 were detected in 15/18 cases (83.3%) of SCLC, 6.8% (2/29) of NSCLC and 7.7% (1/13) of pneumonia. Further, the samples with lymphatic metastasis had remarkable higher positive PAX2 or PAX5 than that without metastases. Overall, our data indicated that PAX2 and PAX5 differentially expressed in NSCLC and SCLC. Thus, PAX2 and PAX5 are useful biomarker in the differential diagnosis of lung cancer.
Subject(s)
Biomarkers, Tumor/analysis , Carcinoma, Non-Small-Cell Lung/diagnosis , Lung Neoplasms/diagnosis , PAX2 Transcription Factor/biosynthesis , PAX5 Transcription Factor/biosynthesis , Small Cell Lung Carcinoma/diagnosis , Adult , Aged , Diagnosis, Differential , Female , Humans , Immunohistochemistry , Male , Middle Aged , PAX2 Transcription Factor/analysis , PAX5 Transcription Factor/analysisABSTRACT
PURPOSE: Sjögren's syndrome (SS) is a common autoimmune disease that can cause aqueous-deficient dry eye and the aberrant differentiation of ocular mucosal epithelial cells toward a lineage that is pathologically keratinized and skin-like. PAX6 is the master regulator of corneal lineage commitment. Recently, we showed a functional role for PAX6 in preventing ocular surface damage induced by the proinflammatory cytokine, IL-1ß, in a mouse model of SS. Here, we examine PAX6's potential as a clinical biomarker that predicts ocular surface disease in SS patients. METHODS: Impression cytology specimens isolated from the bulbar conjunctiva of control (n = 43) and SS patients (n = 43) were used to evaluate the relative abundance of PAX6, IL-1ß, and pathologic keratinization marker, small proline-rich protein (SPRR1B) by TaqMan qPCR. Transcript expression was examined relative to clinical data, including the ocular staining score (OSS), tear breakup time (TBUT), Schirmer tear test, serum autoantibody results, and the labial salivary gland focus score. RESULTS: PAX6 expression was significantly reduced in SS patients (P = 0.010, Wilcoxon rank sum test), and highly correlated with OSS (Spearman ρ = 0.239, 95% CI 0.02-0.43; P = 0.027). The extent to which PAX6 predicted SPRR1B was largely dependent on IL-1ß expression (R(2) = 0.28, P < 0.01) and elevated IL-1ß predicted reduced TBUT (R(2) = 0.24, P = 0.035), low tear secretion (R(2) = 0.30, P = 0.011), and focus score (R(2) = 0.21, P = 0.002). CONCLUSIONS: Downregulation of PAX6 in SS patients was highly associated with ocular surface damage and largely dependent on the level of inflammation. Restoration of PAX6 may provide a clinical approach to manage dry eye in SS patients.
Subject(s)
Down-Regulation , Keratoconjunctivitis Sicca/genetics , PAX5 Transcription Factor/genetics , RNA/genetics , Sjogren's Syndrome/genetics , Biomarkers/metabolism , Conjunctiva/metabolism , Conjunctiva/pathology , Female , Humans , Keratoconjunctivitis Sicca/metabolism , Keratoconjunctivitis Sicca/pathology , Male , Middle Aged , PAX5 Transcription Factor/biosynthesis , Phenotype , Polymerase Chain Reaction , Sjogren's Syndrome/metabolism , Sjogren's Syndrome/pathologyABSTRACT
Although CD138 expression is a hallmark of plasma cells and myeloma cells, reduced CD138 expression is occasionally found. However, the mechanisms underlying CD138 downregulation in myeloma cells remain unclear. Previous reports suggest that the bone marrow microenvironment may contribute to CD138 downregulation. Among various factors in the tumor microenvironment, hypoxia is associated with tumor progression, poor clinical outcomes, dedifferentiation and the formation of cancer stem cell niches in solid tumors. Since recent findings showed that progression of multiple myeloma (MM) delivers hypoxia within the bone marrow, we hypothesized that CD138 expression may be regulated by hypoxia. In the present study, we examined whether the expression of CD138 and transcription factors occurred in myeloma cells under hypoxic conditions. MM cell lines (KMS-12BM and RPMI 8226) were cultured under normoxic or hypoxic conditions for up to 30 days. Changes in the phenotype and the expression of surface antigens and transcription factors were analyzed using flow cytometry, RT-PCR and western blotting. All-trans retinoic acid (ATRA) was used to examine the phenotypic changes under hypoxic conditions. The expression levels of CD138, CS1 and plasma cell-specific transcription factors decreased under hypoxic conditions, while those of CD20, CXCR4 and B cell-specific transcription factors increased compared with those under normoxic conditions. Stem cell-specific transcription factors were upregulated under hypoxic conditions, while no difference was observed in ALDH activity. The reduced CD138 expression under hypoxic conditions recovered when cells were treated with ATRA, even under hypoxic conditions, along with decreases in the expression of stem cell-specific transcription factor. Interestingly, ATRA treatment sensitized MM cells to bortezomib under hypoxia. We propose that hypoxia induces immature and stem cell-like transcription phenotypes in myeloma cells. Taken together with our previous observation that decreased CD138 expression is correlated with disease progression, the present data suggest that a hypoxic microenvironment affects the phenotype of MM cells, which may correlate with disease progression.
Subject(s)
Cell Hypoxia/physiology , Multiple Myeloma/metabolism , Neoplastic Stem Cells/metabolism , Syndecan-1/metabolism , Aldehyde Oxidoreductases/metabolism , Antigens, CD20/biosynthesis , Antineoplastic Agents/pharmacology , Apoptosis/drug effects , Boronic Acids/pharmacology , Bortezomib , Cell Differentiation/drug effects , Cell Line, Tumor , Down-Regulation , Humans , Intercellular Signaling Peptides and Proteins , Oxygen , PAX5 Transcription Factor/biosynthesis , Peptides/metabolism , Pyrazines/pharmacology , Receptors, CXCR4/biosynthesis , Syndecan-1/biosynthesis , Tretinoin/pharmacology , Tumor MicroenvironmentABSTRACT
B-lymphocyte-induced maturation protein 1 (Blimp-1) is the master regulator of plasma cell development, controlling genes such as those encoding J-chain and secretory Ig heavy chain. However, some mammalian plasma cells do not express J-chain, and mammalian B1 cells secrete "natural" IgM antibodies without upregulating Blimp-1. While these results have been controversial in mammalian systems, here we describe subsets of normally occurring Blimp-1(-) antibody-secreting cells in nurse sharks, found in lymphoid tissues at all ontogenic stages. Sharks naturally produce large amounts of both pentameric (classically "19S") and monomeric (classically "7S") IgM, the latter an indicator of adaptive immunity. Consistent with the mammalian paradigm, shark Blimp-1 is expressed in splenic 7S IgM-secreting cells, though rarely detected in the J-chain(+) cells producing 19S IgM. Although IgM transcript levels are lower in J-chain(+) cells, these cells nevertheless secrete 19S IgM in the absence of Blimp-1, as demonstrated by ELISPOT and metabolic labeling. Additionally, cells in the shark BM equivalent (epigonal) are Blimp-1(-). Our data suggest that, in sharks, 19S-secreting cells and other secreting memory B cells in the epigonal are maintained for long periods without Blimp-1, but like in mammals, Blimp-1 is required for terminating the B-cell program following an adaptive immune response in the spleen.
Subject(s)
Immunoglobulin J-Chains/biosynthesis , Immunoglobulin M/biosynthesis , Plasma Cells/metabolism , Repressor Proteins/metabolism , Sharks/immunology , Animals , Cell Differentiation/immunology , Immunoglobulin J-Chains/immunology , Immunoglobulin M/immunology , PAX5 Transcription Factor/biosynthesis , Plasma Cells/immunology , Spleen/metabolism , Up-RegulationABSTRACT
AIMS: The purpose of this study was to evaluate the expression patterns of B-cell specific activator protein (BSAP)/PAX5 and PAX8 in a wide variety of B-cell and T-cell neoplasms. METHODS AND RESULTS: A wide range of B-cell and T-cell neoplasms were subjected to immunohistochemical staining with antibodies against BSAP/PAX5 and PAX8 (polyclonal, pPAX8; monoclonal, mPAX8). Ten non-neoplastic lymph node specimens were examined with the same panel. All of the tested neoplastic and non-neoplastic B-cells reacted with the BSAP/PAX5 and pPAX8 antibodies, but did not show reactivity with the mPAX8 antibody. All tested T-cell neoplasms were negative using the BSAP/PAX5, pPAX8 and mPAX8 antibodies. CONCLUSIONS: This is the first study to show the absence of reactivity to an mPAX8 antibody in an expanded panel of B-cell lymphomas as well as in a variety of T-cell neoplasms. In contrast to the mPAX8 antibody, the pPAX8 antibody shows nuclear positivity in non-neoplastic B cells and mature B-cell neoplasms; however, this expression is probably a result of cross-reactivity with PAX5. Given that many laboratories use the pPAX8 antibody, a clear understanding of the differential staining patterns is necessary. The differential diagnosis of a B-cell lymphoma should be entertained when a pPAX8-positive, epithelial marker-negative neoplasm of uncertain primary origin is encountered.
Subject(s)
Biomarkers, Tumor/analysis , Lymphoma, B-Cell/metabolism , Lymphoma, T-Cell/metabolism , PAX5 Transcription Factor/biosynthesis , Paired Box Transcription Factors/biosynthesis , Humans , Immunohistochemistry , Lymphoma, B-Cell/diagnosis , Lymphoma, T-Cell/diagnosis , PAX5 Transcription Factor/analysis , PAX8 Transcription Factor , Paired Box Transcription Factors/analysisABSTRACT
Mesenchymal stem cells (MSCs) may be obtained from umbilical cord as an abundant and noninvasive source. However, the immunomodulatory properties of umbilical cord-MSCs (UC-MSCs) were poorly studied. In this study, we aimed to investigate the effects of UC-MSCs on B-cell proliferation and differentiation. UC-MSCs were found to suppress the proliferation of B cells isolated from murine spleen. Moreover, UC-MSCs markedly suppressed B-cell differentiation as shown by the decreased number of CD138+cells and reduced levels of IgM and IgG production in coculture. As revealed by transwell experiments, soluble factors produced by UC-MSCs might be involved in mediating B-cell suppression. The Blimp-1 mRNA expression was suppressed whereas the PAX-5 mRNA expression was induced in coculture. Finally, UC-MSCs modified the phosphorylation pattern of Akt and p38 pathways, which were involved in B-cell proliferation and differentiation. These results may further support the potential therapeutic use of UC-MSCs in treating autoimmune disorders.
Subject(s)
B-Lymphocytes/immunology , Mesenchymal Stem Cells/immunology , PAX5 Transcription Factor/biosynthesis , Transcription Factors/biosynthesis , Animals , B-Lymphocytes/metabolism , Cell Differentiation , Cell Proliferation , Cells, Cultured , Coculture Techniques , Female , Immunoglobulin G/biosynthesis , Immunoglobulin M/biosynthesis , Mice , Mice, Inbred C57BL , PAX5 Transcription Factor/genetics , Phosphorylation , Positive Regulatory Domain I-Binding Factor 1 , Proto-Oncogene Proteins c-akt/metabolism , RNA, Messenger/biosynthesis , Syndecan-1/biosynthesis , Transcription Factors/genetics , Umbilical Cord/immunology , p38 Mitogen-Activated Protein Kinases/metabolismABSTRACT
Patients without chronic graft-versus-host disease (cGVHD) have robust B cell reconstitution and are able to maintain B cell homeostasis after allogeneic hematopoietic stem cell transplantation (HSCT). To determine whether B lymphopoiesis differs before cGVHD develops, we examined bone marrow (BM) biopsies for terminal deoxynucleotidyl transferase (TdT) and PAX5 immunostaining early post-HSCT at day 30 when all patients have been shown to have high B cell activating factor (BAFF) levels. We found significantly greater numbers of BM B cell precursors in patients who did not develop cGVHD compared with those who developed cGVHD (median = 44 vs 2 cells/high powered field [hpf]; respectively; P < .001). Importantly, a significant increase in precursor B cells was maintained when patients receiving high-dose steroid therapy were excluded (median = 49 vs 20 cells/hpf; P = .017). Thus, we demonstrate the association of BM B cell production capacity in human GVHD development. Increased BM precursor B cell number may serve to predict good clinical outcome after HSCT.